Efficacy assessment of azithromycin 1.5 % eye drops versus tobramycin 0.3 % on clinical signs of purulent bacterial conjunctivitis;Évaluation de l'efficacité d'un collyre azithromycine 1,5 % versus tobramycine 0,3 % sur les signes cliniques de la conjonctivite bactérienne purulente

Journal Francais d'Ophtalmologie

Volumn 33, Issue 4, 2010, Pages 241-248

  Robert, P Y ^a   Bourcier, T ^a   Meddeb Ouertani, A ^a   Khairallah, M ^a   Zaghloul, K ^a   Amraoui, A ^a   Bhagat, Y ^a   Pop, M ^a   Cochereau, I ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Azithromycin 1.5 ; Clinical signs; Purulent bacterial conjunctivitis; Symptoms

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; EYE DROPS; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EDEMA; ERYTHEMA; EYELID DISEASE; FOLLOW UP; HUMAN; HYPEREMIA; INFANT; MIDDLE AGED; MULTICENTER STUDY; NEWBORN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; SUPPURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CONJUNCTIVA; CONJUNCTIVITIS, BACTERIAL; EDEMA; ERYTHEMA; EYELID DISEASES; FOLLOW-UP STUDIES; HUMANS; HYPEREMIA; INFANT; INFANT, NEWBORN; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SAFETY; SINGLE-BLIND METHOD; SUPPURATION; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953139093     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2010.01.005     Document Type: Article

References (36)

1. Hwang D.G. Bacterial conjunctivitis. In: Pepose J.S., Holland G.N., and Wilhelmus K.R. (Eds). Ocular infection & immunity. 62 (1996), Mosby, Saint-Louis, USA 799-817
2. Sheikh A., Hurwitz B., and Cave J. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2 (2000) CD001211
3. Sheikh A., and Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 51 (2001) 473-477
4. Sheikh A., and Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2 (2006) CD001211
5. Hwang D.G., Schanzlin D.J., Rotberg M.H., Foulks G., and Raizman M.B. A phase III, placebo controlled clinical trial of 0.5 % levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 87 (2003) 1004-1009
6. Afssaps. Recommandations. Collyres et autres topiques antibiotiques dans les infections oculaires superficielles. 2004; 1-6.
7. Gaynor B.D., Miao Y., Cevallos V., Jha H., Chaudary J.S., Bhatta R., et al. Eliminating trachoma in areas with limited disease. Emerg Infect Dis 9 (2003) 596-598
8. Jaruratanasirikul S., Hortiwakul R., Tantisarasart T., Phuenpathom N., and Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 40 (1996) 825-826
9. Retsema J., Girard A., Schelkly W., Manousos M., Anderson M., Bright G., et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 31 (1987) 1939-1947
10. Bowman R.J., Sillah A., Van Dehn C., Goode V.M., Muquit M., Johnson G.J., et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci 41 (2000) 4074-4079
11. Tabbara K.F., Abu-el-Asrar A., al-Omar O., Choudhury A.H., and al-Faisal Z. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 103 (1996) 842-846
12. Van Bambeke F., and Tulkens P.M. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 18 Suppl 1 (2001) S17-S23
13. Amar T., Caillaud T., and Elena P.P. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Curr Eye Res 33 (2008) 149-158
14. Fechner P.U., and Teichmann K.D. The conjunctiva. In: Fechner P.U., and Teichmann K.D. (Eds). Ocular therapeutics pharmacology and clinical application. 15 (1998), Slack Inc, Thorofare, USA 285-326
15. Morrow G.L., and Abbott R.L. Conjunctivitis. Am Fam Physician 57 (1998) 735-746
16. Soukiasian S.H., and Baum J. Bacterial conjunctivitis. In: Krachmer J.H., Mannis M.J., and Holland E.J. (Eds). Cornea. 2nd Edition 49 (2005), Elsevier Mosby, Philadelphie, USA 615-628
17. Syed N.A., and Chandler J.W. Bacterial conjunctivitis. In: Tabbara K.F., and Hyndiuk R.A. (Eds). Infections of the eye. 27 (1996), Little, Brown and Co, Boston, USA 423-431
18. Lichtenstein S.J., and Rinehart M. Efficacy and safety of 0.5 % levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS 7 (2003) 317-324
19. Schwab I.R., Friedlaender M., McCulley J., Lichtenstein S.J., and Moran C.T. A phase III clinical trial of 0.5 % levofloxacin ophthalmic solution versus 0.3 % ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110 (2003) 457-465
20. Silver L.H., Burkey R., Montgomery D., Gower L., Dickerson J., Crenshaw K., et al. Safety of Ophthalmic Moxifloxacin in the Treatment of Newborns, Infants and Toddlers, Children, and Adolescents With Bacterial Conjunctivitis. ARVO. Fort Lauderdale, USA, May 4-9, 2003. Invest Ophthalmol Vis Sci 44 (2003) 804
21. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. 22 avril 2004. The European Agency for the Evaluation of Medicinal Products (EMEA). London, United Kingdom. 2004; CPMP/EWP/558/95 rev 1: 1-22.
22. Cochereau I., Meddeb-Ouertani A., Khairallah M., Amraoui A., Zaghloul K., Pop M., et al. 3-day treatment with azithromycin 1.5 % eye drops versus 7-day treatment with tobramycin 0.3 % for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 91 (2007) 465-469
23. Bloom P.A., Leeming J.P., Power W., Laidlaw D.A., Collum L.M., and Easty D.L. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. Eur J Ophthalmol 4 (1994) 6-12
24. Fioretti G.M., and Campanari C. Le congiuntiviti di origine batterica in eta pediatrica. Trattamento antibiotico locale con tobramicina collirio. Pediatr Med Chir 11 (1989) 421-423
25. Gallenga P.E., Lobefalo L., Colangelo L., Della L.G., Orzalesi N., Velati P., et al. Topical lomefloxacin 0.3 % twice daily versus tobramycin 0.3 % in acute bacterial conjunctivitis: a multicenter double-blind phase III study. Ophthalmologica 213 (1999) 250-257
26. Gross R.D., Hoffman R.O., and Lindsay R.N. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr (Phila) 36 (1997) 435-444
27. Gwon A. Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol 110 (1992) 1234-1237
28. Jackson W.B., Low D.E., Dattani D., Whitsitt P.F., Leeder R.G., and MacDougall R. Treatment of acute bacterial conjunctivitis: 1 % fusidic acid viscous drops vs. 0. 3 % tobramycin drops. Can J Ophthalmol 37 (2002) 228-237
29. Jacobson J.A., Call N.B., Kasworm E.M., Dirks M.S., and Turner R.B. Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections. Antimicrob Agents Chemother 32 (1988) 1820-1824
30. Jauch A., Fsadni M., and Gamba G. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3 % eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. Graefes Arch Clin Exp Ophthalmol 237 (1999) 705-713
31. Leibowitz H.M., Hyndiuk R.A., Smolin G.R., Nozik R.A., Hunter G.J., Cagle G.D., et al. Tobramycin in external eye disease: a double-masked study vs. gentamicin. Curr Eye Res 1 (1981) 259-266
32. Leibowitz H.M. Antibacterial effectiveness of ciprofloxacin 0.3 % ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 112 4 Suppl (1991) 29S-33S
33. Milazzo G., Papa V., Carstocea B., Chercota G., Rodica P., Gafencu O., et al. Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther 37 (1999) 243-248
34. Tabbara K.F., El Sheikh H.F., Islam S.M., and Hammouda E. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3 % compared to topical ofloxacin 0.3 %. Eur J Ophthalmol 9 (1999) 269-275
35. Yee R.W., Tepedino M., Bernstein P., Jensen H., Schiffman R., and Whitcup S.M. A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3 % administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. Curr Med Res Opin 21 (2005) 425-431
36. Chiambaretta F., Garraffo R., Elena P.P., Pouliquen P., Delval L., Rigal D., et al. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5 %, 1.0 %, and 1.5 % eyedrops (T1225) in healthy volunteers. Eur J Ophthalmol 18 (2008) 13-20